Market Cap: $16.79M
PI
PAVmed Inc.
PAVM
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $16.79M
PAVmed Inc (Ticker: PAVM) showcases substantial advancements in its business operations and financial results for the first quarter of 2026. The latest earnings call emphasizes the company's strategic…
PAVmed Appoints New Chief Business Officer to Drive Medical Device Innovation PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, takes a significant step forward by appointing…
PAVmed restructures capital to back EsoGuard commercialization PAVmed Inc. is closing a financing and capital restructuring designed to remove legacy convertible instruments and better support commerc…
PAVmed closes financing to clear legacy capital roadblocks and back EsoGuard rollout Capital restructuring to accelerate EsoGuard commercialization PAVmed Inc. is closing a financing package aimed at…
PAVmed Restructures to Clear Legacy Overhang PAVmed Inc. is recasting its capital structure to remove longstanding convertible securities that the company says have constrained its commercial strategy…
Expanding Access to Esophageal Cancer Screening for Veterans Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., has recently secured a significant contract with the U.S. Department of Veterans Affai…
PAVmed's Strategic Focus on Esophageal Cancer Diagnostics PAVmed Inc. positions itself as a diversified medical technology company, concentrating on innovative solutions in the medical device, diagnos…
### Breakthrough Study Validates EsoGuard® as a Key Tool for Esophageal Cancer Screening Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., announces the findings of the largest real-world study on…
Lucid Diagnostics Advances Esophageal Cancer Prevention Efforts Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., is making significant strides in the field of cancer prevention, specifically targe…
PAVmed's Role in Medical Innovation Amidst Financial Reporting In the healthcare sector, PAVmed stands out as a company dedicated to developing innovative medical technologies that address unmet needs…
Lucid Diagnostics Enhances Commitment to Cancer Prevention with Upcoming Forum Participation Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., is set to participate in the Canaccord Genuity MedTech…
Lucid Diagnostics Expands Reach in Cancer Prevention at Upcoming MedTech Forum Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., announces its participation in the Canaccord Genuity MedTech, Diagno…
PAVmed Unveils Veris Cancer Care Platform in Collaboration with Ohio State University Comprehensive Cancer Center PAVmed Inc. (Nasdaq: PAVM), a diversified medical technology enterprise, announces the…
PAVmed's Innovative Partnership Enhances Cancer Care Through Technology PAVmed Inc., a prominent player in the medical technology sector, marks a significant advancement in cancer treatment with the c…
PAVmed Partners with OSUCCC to Enhance Cancer Care through Technology PAVmed Inc. is making significant strides in cancer treatment technology with the commercial launch of its Veris Cancer Care Platf…
PAVmed Partners with Duke University to Advance Esophageal Dysplasia Diagnosis PAVmed Inc., a diversified medical technology company, is making significant strides in the realm of esophageal dysplasia…
PAVmed Partners with Duke University to Advance Esophageal Dysplasia Diagnosis PAVmed Inc. has recently strengthened its position in the medical technology landscape by signing a non-binding letter of…
PAVmed Partners with Duke University to Transform Esophageal Cancer Diagnostics PAVmed Inc., a diversified medical technology company, announces a strategic partnership with Duke University to advance…